Description

Retatrutide 12 mg is the highest clinical trial dose of this next-generation investigational peptide. Acting as a triple receptor agonist (GLP-1, GIP, and glucagon), it has shown unprecedented results in weight loss, glucose control, and metabolic health during Phase 2 and 3 trials.

The 12 mg weekly dose represents the upper titration limit used in studies, typically following gradual increases from 2 mg → 5 mg → 8 mg → 10 mg → 12 mg. Early trial data suggest that participants at this strength achieved over 24% average body weight reduction across 48 weeks — positioning Retatrutide as one of the most powerful obesity treatments in development.

⚠️ Status: Research-only. Not yet approved for medical use (FDA/MHRA approval expected ~2026–2027).